iBio, Inc. Files 8-K Report

Ticker: IBIO · Form: 8-K · Filed: 2025-04-07T00:00:00.000Z

Sentiment: neutral

Topics: 8-k, sec-filing, disclosure

TL;DR

iBio filed a routine 8-K, no major news.

AI Summary

On April 7, 2025, iBio, Inc. filed an 8-K report detailing a Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond the standard reporting requirements.

Why It Matters

This 8-K filing serves as a standard disclosure for iBio, Inc., providing updates on financial statements and other events as required by the SEC.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report with no new material information that would significantly impact the company's risk profile.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by iBio, Inc.?

The primary purpose of this 8-K filing is to report a Regulation FD Disclosure, Other Events, and to include Financial Statements and Exhibits as of April 7, 2025.

What is the date of the earliest event reported in this filing?

The date of the earliest event reported in this filing is April 7, 2025.

In which state was iBio, Inc. incorporated?

iBio, Inc. was incorporated in Delaware.

What is the Commission File Number for iBio, Inc.?

The Commission File Number for iBio, Inc. is 001-35023.

What is the address of iBio, Inc.'s principal executive offices?

The address of iBio, Inc.'s principal executive offices is 11750 Sorrento Valley Road Suite 200 San Diego, California 92121.

From the Filing

0001420720-25-000016.txt : 20250407 0001420720-25-000016.hdr.sgml : 20250407 20250407070151 ACCESSION NUMBER: 0001420720-25-000016 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20250407 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250407 DATE AS OF CHANGE: 20250407 FILER: COMPANY DATA: COMPANY CONFORMED NAME: iBio, Inc. CENTRAL INDEX KEY: 0001420720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 262797813 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35023 FILM NUMBER: 25816350 BUSINESS ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 BUSINESS PHONE: 302 355-0650 MAIL ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 FORMER COMPANY: FORMER CONFORMED NAME: iBioPharma, Inc. DATE OF NAME CHANGE: 20080806 FORMER COMPANY: FORMER CONFORMED NAME: InB:Biotechnologies, Inc. DATE OF NAME CHANGE: 20071210 8-K 1 ibio-20250407x8k.htm 8-K iBio, Inc._April 7, 2025 0001420720 false 0001420720 2025-04-07 2025-04-07 ​ ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM  8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 7, 2025 iBio, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) ​ ​ 001-35023 26-2797813 (Commission File Number) (IRS Employer Identification No.) ​ 11750 Sorrento Valley Road Suite 200 San Diego, California 92121 (Address of principal executive offices and zip code) ( 979 ) 446-0027 (Registrant’s telephone number including area code) N/A (Former Name and Former Address) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions: ☐       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐       Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12) ☐       Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐       Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: ​ ​ ​ Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock , $0.001 par value per share IBIO NYSE American ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company   ☐ If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ ​ ​ ​ ​ Item 7.01. Regulation FD Disclosure. ​ On April 7, 2025, iBio, Inc., (the “Company”) issued a press release announcing data from a non-human primate study of IBIO-600, the Company’s long-acting anti-myostatin antibody, and preclinical data of a first-in-class Activin E antibody. A copy of the press release is furnished herewith as Exhibit 99.1. ​ The non-human primate data showed extended half-life and muscle growth. The results ind

View on Read The Filing